87 related articles for article (PubMed ID: 26688298)
21. Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses.
Tremain AC; Wallace RP; Lorentz KM; Thornley TB; Antane JT; Raczy MR; Reda JW; Alpar AT; Slezak AJ; Watkins EA; Maulloo CD; Budina E; Solanki A; Nguyen M; Bischoff DJ; Harrington JL; Mishra R; Conley GP; Marlin R; Dereuddre-Bosquet N; Gallouët AS; LeGrand R; Wilson DS; Kontos S; Hubbell JA
Nat Biomed Eng; 2023 Sep; 7(9):1142-1155. PubMed ID: 37679570
[TBL] [Abstract][Full Text] [Related]
22. Association of myelin peptide with vitamin D prevents autoimmune encephalomyelitis development.
Mimura LA; Chiuso-Minicucci F; Fraga-Silva TF; Zorzella-Pezavento SF; França TG; Ishikawa LL; Penitenti M; Ikoma MR; Sartori A
Neuroscience; 2016 Mar; 317():130-40. PubMed ID: 26762804
[TBL] [Abstract][Full Text] [Related]
23. [Rapamycin-conditioned dendritic cells induced immune tolerance through the regulation of Treg/Th17 cells in mice].
Yang X; Yao Q; Hu X; Wang W; Yin H; Ren L; Liu H; Zhang X
Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(30):2469-73. PubMed ID: 26711212
[TBL] [Abstract][Full Text] [Related]
24. Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
Funda DP; Palová-Jelínková L; Goliáš J; Kroulíková Z; Fajstová A; Hudcovic T; Špíšek R
Front Immunol; 2019; 10():967. PubMed ID: 31139178
[TBL] [Abstract][Full Text] [Related]
25. Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation.
Serrano I; Luque A; Aran JM
Front Immunol; 2018; 9():892. PubMed ID: 29760704
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Effects of 1,25-Dihydroxyvitamin D
Lee WP; Willekens B; Cras P; Goossens H; Martínez-Cáceres E; Berneman ZN; Cools N
J Immunol Res; 2016; 2016():5392623. PubMed ID: 27703987
[TBL] [Abstract][Full Text] [Related]
27. Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs.
van Kooten C; Stax AS; Woltman AM; Gelderman KA
Handb Exp Pharmacol; 2009; (188):233-49. PubMed ID: 19031029
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
[TBL] [Abstract][Full Text] [Related]
29. Selective depletion of CD11c
Wang L; Li Z; Ciric B; Safavi F; Zhang GX; Rostami A
Eur J Immunol; 2016 Oct; 46(10):2454-2466. PubMed ID: 27338697
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis.
Zhou F; Ciric B; Zhang GX; Rostami A
Clin Exp Immunol; 2014 Dec; 178(3):447-58. PubMed ID: 25138204
[TBL] [Abstract][Full Text] [Related]
31. Delivery of alloantigens via apoptotic cells generates dendritic cells with an immature tolerogenic phenotype.
Gleisner MA; Rosemblatt M; Fierro JA; Bono MR
Transplant Proc; 2011; 43(6):2325-33. PubMed ID: 21839264
[TBL] [Abstract][Full Text] [Related]
32. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Ge Z; Da Y; Xue Z; Zhang K; Zhuang H; Peng M; Li Y; Li W; Simard A; Hao J; Yao Z; Zhang R
Exp Neurol; 2013 Mar; 241():56-66. PubMed ID: 23261766
[TBL] [Abstract][Full Text] [Related]
33. Tolerogenic Dendritic Cells Generated by In Vitro Treatment With SAHA Are Not Stable In Vivo.
Thewissen K; Broux B; Hendriks JJ; Vanhees M; Stinissen P; Slaets H; Hellings N
Cell Transplant; 2016; 25(6):1207-18. PubMed ID: 26688298
[TBL] [Abstract][Full Text] [Related]
34. Induction of tolerogenic dendritic cells by vitamin D receptor agonists.
Adorini L; Penna G
Handb Exp Pharmacol; 2009; (188):251-73. PubMed ID: 19031030
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
